Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies Meeting Abstract
| Authors: | Pollyea, D. A.; de Botton, S.; Fathi, A. T.; Stein, E. M.; Tallman, M. S.; Agresta, S.; Bowden, C.; Fan, B.; Prah, M.; Yang, H.; Yen, K.; Stone, R. M. |
| Abstract Title: | Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies |
| Meeting Title: | 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 50 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2014 Nov 18-21 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-11-01 |
| Start Page: | 195 |
| Language: | English |
| ACCESSION: | WOS:000347755700597 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(14)70722-1 |
| Notes: | Meeting Abstract: 1LBA -- 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 18-21, 2014 -- Barcelona, SPAIN -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work